Post Operative Pain and Vagal Stimulation (VAGANAL)
"Evolution of Postoperative Anal Pain Following Elective Proctological or Rectal Surgery Under the Effect of Transcutaneous Vagal Auricular Stimulation: a Feasibility Study - VAGANAL - Postoperative Pain and Vagal Stimulation"
Anorectal surgery is a type of surgery that can cause anal pain, particularly in the context of hemorrhoid surgery or anal fissure surgery. Generally, the period of discomfort related to the pain lasts about two weeks. There is a nerve (the vagus nerve) whose stimulation via a probe placed in the ear can reduce stress and chronic pain. Its ease of use makes it a promising tool for treating pain. Vagal auricular stimulation could be an interesting option in the management of postoperative pain of the anus and rectum. Its efficacy or feasibility in this context has never been evaluated.
The aim of this study is to evaluate the feasibility in this context and to assess the extend of pain reduction associated with perioperative nerve vagus stimulation by a medical device (Transcutaneous Electrical Nerve Stimulator (TENS ECO Plus)). It is offered to adult patients undergoing transanal anal or rectal surgery on an outpatient or inpatient basis as part of a scheduled procedure.
Patients to be included in the study are selected during the initial pre-operative consultation with the surgeon. Once the surgical indication is confirmed and the patient fulfills the study eligibility criteria, the investigator provides them with oral information about the study. The patient is also given an information sheet (written in language understandable to the patient) and a consent form.
During this initial visit, demographic data and information regarding the surgical indication are collected.
Stimulation begins two days before surgery (twice daily), followed by stimulation on the morning of surgery, one hour before arrival in the operating room. Successful completion of the stimulation, as well as any complications, are recorded in the patient diary.
On the day of surgery (day 0), data concerning the procedure and the maximum visual analogue scale (VAS) are collected in the recovery room. Analgesic consumption is also recorded.
On the evening of the procedure, stimulation is performed and adherence is recorded.
Maximum and mean VAS are collected on postoperative day 1 and then daily in the patient diary for 15 days.
Vagus nerve stimulation is performed morning and evening for 15 days. VAS scores, adherence, analgesic consumption, the date of the first bowel movement and its painfulness, as well as any complications related to the stimulation are noted in the patient diary. On day 3 (+/- 2 days) after the procedure, and at the end of the 15-day postoperative period, the patient will be contacted by phone or text message by the investigator team to remind them to complete the notebook.
On day 30 (+/- 5 days), the patient returns for a follow-up visit. The patient diary and equipment are collected. Complications are recorded, as well as quality of life during the postoperative month (SF-36 form).
For patients, the expected benefits are significant, as postoperative quality of life is expected to improve through reduced pain. Furthermore, decreasing the use of step II and III analgesics should shorten the recovery period and promote better overall recovery.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Sarfati Marine, MD
- Telefonnummer: +33 2 41 35 36 17
- E-post: Marine.SarfatiLebreton@chu-angers.fr
Studieorter
-
-
Maine et Loire
-
Angers, Maine et Loire, Frankrike, 49933
- Angers Hospital
-
Kontakt:
- venara aurélien, MD, PhD
- Telefonnummer: +33 2 41 35 36 18
- E-post: AuVenara@chu-angers.fr
-
Huvudutredare:
- sarfati Marine, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Adult patient
- Underwent anal or rectal surgery via the transanal route
- Managed on an outpatient basis or in conventional hospitalization
- Having signed a consent to participate in the study
Exclusion Criteria:
- Patient operated on as an emergency
- Rectal surgery via abdominal approach or requiring an abdominal approach during the procedure
- Known epileptic patient
- Patient with a pacemaker
- Patient refusing to participate in the study
- Pregnant, breastfeeding, or laboring woman
- Patient not affiliated with a social security scheme
- Person deprived of liberty by judicial or administrative decision
- Person subject to compulsory psychiatric care - Any contraindication mentioned in the instructions for use of the medical device under investigation
Exclusion Criteria:
- Unscheduled conversion from the transanal route to the abdominal route during surgery
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: active nerve vagus stimulator
assessment of rectal post operative pain with active nerve vagus stimulation
|
active vagus nerve stimulation
|
|
Sham Comparator: control arm
assessment of rectal post operative pain without active nerve vagus stimulation
|
no active vagus nerve stimulation
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
consumption of analgesic
Tidsram: From Day 0 to Day 15
|
the post-operative consumption of analgesic is evaluated in the recovery room (day 0) and then every day for 15 days.
Post-operative consumption is assessed in patients treated with auricular vagus active nerve stimulation and in patients with a inactive device.
|
From Day 0 to Day 15
|
|
Change of pain after perioperative auricular vagus nerve stimulation
Tidsram: day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 13, day 14, day 15
|
The intensity of anal pain is measured by the Visual Analog Scale (VAS) from 0 to 10 in the recovery room and then every day for 15 days.
This VAS is assessed in patients treated with auricular vagus active nerve stimulation and in patients with a inactive device.
The higher score means a worse outcome.
|
day 0, day 1, day 2, day 3, day 4, day 5, day 6, day 7, day 8, day 9, day 10, day 11, day 12, day 13, day 14, day 15
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
adverse events
Tidsram: day 30
|
adverse events occuring during the first month after surgery and specifically related to the surgery are collected by the investigator for the two groups of patients
|
day 30
|
|
acceptability of perioperative auricular vagus nerve stimulation by the patient
Tidsram: day 15
|
The acceptability of treatment by perioperative auricular vagal stimulation is assessed at day 15 by asked question to the two groups of patients.
The question is "do you think that the treatment with vagus nerve stimulation is non-binding?"
|
day 15
|
|
Delay in gastrointestinal motility recovery (passage of stool) and post-defecatory pain
Tidsram: from day 0 to day 30
|
The gastrointestinal transit recovery after surgery is recorded in the patients treated with active device and in patients treated with inactive device.
Post defecatory pain more than 30 min is also reported in the patients with active and with inactive device.
|
from day 0 to day 30
|
|
Quality of life of patients after surgery
Tidsram: Day 30
|
quality of life by health survey SF 36 (the 36-item Short Form Health Survey) is assessed at the day 30 after surgery in the two groups of patients (active device and no active device).
SF 36 covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items).
Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.
|
Day 30
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 49RC25-0293
- 2026-A01004-47 (Annan identifierare: ANSM)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .